美国食品和药物管理局批准新型肺癌药物恩萨尔提尼布用于ALK阳性患者,显示更好的生存率. FDA approves new lung cancer drug ensartinib for ALK-positive patients, showing better survival rates.

食品及药物管理局已核准Ensartinib(Ensacove)治疗未接受过过去ALK抑制剂治疗的成人患ALK阳性非小细胞肺癌。 The FDA has approved ensartinib (Ensacove) for treating adults with ALK-positive non-small cell lung cancer who haven't received previous ALK inhibitor treatment. 在第三阶段试验中,与Crizotinib相比,ensartinib的中位无进步生存率翻了一番,其副作用包括皮疹、肌肉疼痛和疲劳。 In a phase 3 trial, ensartinib doubled median progression-free survival compared to crizotinib, with common side effects including rash, muscle pain, and fatigue. 建议的剂量是每天225毫克。 The recommended dose is 225 mg daily.